CN104069486B - 一种含有胰激肽原酶的药物组合物及其制剂 - Google Patents
一种含有胰激肽原酶的药物组合物及其制剂 Download PDFInfo
- Publication number
- CN104069486B CN104069486B CN201310105812.8A CN201310105812A CN104069486B CN 104069486 B CN104069486 B CN 104069486B CN 201310105812 A CN201310105812 A CN 201310105812A CN 104069486 B CN104069486 B CN 104069486B
- Authority
- CN
- China
- Prior art keywords
- kallidinogenase
- poloxamer
- pharmaceutical composition
- gained
- mix homogeneously
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 102000001399 Kallikrein Human genes 0.000 title claims abstract description 50
- 108060005987 Kallikrein Proteins 0.000 title claims abstract description 50
- 229960003709 kallidinogenase Drugs 0.000 title claims abstract description 49
- 238000002360 preparation method Methods 0.000 title claims abstract description 25
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 24
- 239000000825 pharmaceutical preparation Substances 0.000 title abstract description 7
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims abstract description 26
- 229920001983 poloxamer Polymers 0.000 claims abstract description 26
- 229960000502 poloxamer Drugs 0.000 claims abstract description 26
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 claims abstract description 25
- 239000001540 sodium lactate Substances 0.000 claims abstract description 25
- 229940005581 sodium lactate Drugs 0.000 claims abstract description 25
- 235000011088 sodium lactate Nutrition 0.000 claims abstract description 25
- 239000000203 mixture Substances 0.000 claims description 90
- 239000008187 granular material Substances 0.000 claims description 28
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 22
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 claims description 19
- 239000011347 resin Substances 0.000 claims description 19
- 229920005989 resin Polymers 0.000 claims description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 14
- 229920002511 Poloxamer 237 Polymers 0.000 claims description 14
- 230000001476 alcoholic effect Effects 0.000 claims description 14
- 239000011248 coating agent Substances 0.000 claims description 14
- 238000000576 coating method Methods 0.000 claims description 14
- 229960000935 dehydrated alcohol Drugs 0.000 claims description 14
- 239000000843 powder Substances 0.000 claims description 14
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 13
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 13
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 13
- 229960003943 hypromellose Drugs 0.000 claims description 13
- 235000019359 magnesium stearate Nutrition 0.000 claims description 11
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 8
- 229920002472 Starch Polymers 0.000 claims description 8
- 239000011734 sodium Substances 0.000 claims description 8
- 229910052708 sodium Inorganic materials 0.000 claims description 8
- 239000008107 starch Substances 0.000 claims description 8
- 235000019698 starch Nutrition 0.000 claims description 8
- 238000012360 testing method Methods 0.000 abstract description 36
- 238000000034 method Methods 0.000 abstract description 21
- 238000013112 stability test Methods 0.000 abstract description 4
- 238000012216 screening Methods 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 22
- 239000003826 tablet Substances 0.000 description 16
- 206010008118 cerebral infarction Diseases 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 238000009505 enteric coating Methods 0.000 description 8
- 239000002702 enteric coating Substances 0.000 description 8
- 241000700159 Rattus Species 0.000 description 6
- 230000033228 biological regulation Effects 0.000 description 6
- 208000026106 cerebrovascular disease Diseases 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 239000002662 enteric coated tablet Substances 0.000 description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 229940016286 microcrystalline cellulose Drugs 0.000 description 5
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 5
- 239000008108 microcrystalline cellulose Substances 0.000 description 5
- 238000012856 packing Methods 0.000 description 5
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 239000008363 phosphate buffer Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 201000006474 Brain Ischemia Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 101000605527 Rattus norvegicus Kallikrein-1 Proteins 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 102000057032 Tissue Kallikreins Human genes 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000000302 ischemic effect Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000012086 standard solution Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- PKDBCJSWQUOKDO-UHFFFAOYSA-M 2,3,5-triphenyltetrazolium chloride Chemical compound [Cl-].C1=CC=CC=C1C(N=[N+]1C=2C=CC=CC=2)=NN1C1=CC=CC=C1 PKDBCJSWQUOKDO-UHFFFAOYSA-M 0.000 description 2
- 206010000117 Abnormal behaviour Diseases 0.000 description 2
- 206010008120 Cerebral ischaemia Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- ZUAAPNNKRHMPKG-UHFFFAOYSA-N acetic acid;butanedioic acid;methanol;propane-1,2-diol Chemical compound OC.CC(O)=O.CC(O)CO.OC(=O)CCC(O)=O ZUAAPNNKRHMPKG-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 210000003194 forelimb Anatomy 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000004570 mortar (masonry) Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 210000000216 zygoma Anatomy 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- 206010065559 Cerebral arteriosclerosis Diseases 0.000 description 1
- 206010008092 Cerebral artery thrombosis Diseases 0.000 description 1
- 235000007466 Corylus avellana Nutrition 0.000 description 1
- 240000003211 Corylus maxima Species 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 108010025252 Kassinin Proteins 0.000 description 1
- 102000010631 Kininogens Human genes 0.000 description 1
- 108010077861 Kininogens Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- RSYYQCDERUOEFI-JTQLQIEISA-N N-benzoyl-L-arginine Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)C1=CC=CC=C1 RSYYQCDERUOEFI-JTQLQIEISA-N 0.000 description 1
- 235000011203 Origanum Nutrition 0.000 description 1
- 240000000783 Origanum majorana Species 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- UHZZMRAGKVHANO-UHFFFAOYSA-M chlormequat chloride Chemical compound [Cl-].C[N+](C)(C)CCCl UHZZMRAGKVHANO-UHFFFAOYSA-M 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 210000001951 dura mater Anatomy 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000003195 fascia Anatomy 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 201000005851 intracranial arteriosclerosis Diseases 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 229940039088 kininogenase Drugs 0.000 description 1
- 210000004373 mandible Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 210000003657 middle cerebral artery Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 210000000956 olfactory bulb Anatomy 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- SBNFWQZLDJGRLK-UHFFFAOYSA-N phenothrin Chemical compound CC1(C)C(C=C(C)C)C1C(=O)OCC1=CC=CC(OC=2C=CC=CC=2)=C1 SBNFWQZLDJGRLK-UHFFFAOYSA-N 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
Description
组别 | 脑梗塞面积(%) | 行为障碍评分 |
空白组 | 11.6±2.3 | 8.3±1.3 |
对照组 | 8.7±1.2 | 7.6±1.6 |
试验1 | 8.6±1.5* | 7.2±1.1* |
试验2 | 4.8±0.7##* | 5.3±0.6##* |
试验3 | 3.6±0.8##* | 4.9±0.4##* |
试验4 | 1.8±0.4##* | 3.0±0.5##* |
试验5 | 2.1±0.6##* | 3.3±0.3##* |
试验6 | 4.3±0.5##* | 5.0±0.4##* |
编号 | 胰激肽原酶 | 乳酸钠 | 泊洛沙姆237 |
处方1 | 60000单位 | — | 10g |
处方2 | 60000单位 | 2g | 10g |
处方3 | 60000单位 | — | 20g |
处方4 | 60000单位 | 5g | 20g |
组别 | 效价 |
试验1 | 49.8 |
试验2 | 59.2 |
试验3 | 48.7 |
试验4 | 59.8 |
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310105812.8A CN104069486B (zh) | 2013-03-29 | 2013-03-29 | 一种含有胰激肽原酶的药物组合物及其制剂 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310105812.8A CN104069486B (zh) | 2013-03-29 | 2013-03-29 | 一种含有胰激肽原酶的药物组合物及其制剂 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104069486A CN104069486A (zh) | 2014-10-01 |
CN104069486B true CN104069486B (zh) | 2016-04-20 |
Family
ID=51591352
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310105812.8A Active CN104069486B (zh) | 2013-03-29 | 2013-03-29 | 一种含有胰激肽原酶的药物组合物及其制剂 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104069486B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105168168B (zh) * | 2015-10-30 | 2017-12-05 | 成都通德药业有限公司 | 一种胰激肽原酶肠溶片的制备方法 |
CN105287423B (zh) * | 2015-11-02 | 2018-02-23 | 河南灵佑药业股份有限公司 | 一种胰激肽原酶片 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006088305A1 (en) * | 2005-02-15 | 2006-08-24 | Chong Kun Dang Pharmaceutical Corp. | Gastric-retentive controlled release mono-matrix tablet |
CN100384991C (zh) * | 2004-08-20 | 2008-04-30 | 北京赛生药业有限公司 | 高纯度胰激肽原酶的制备方法及其药物制剂 |
CN101134105B (zh) * | 2007-07-02 | 2011-04-20 | 广东天普生化医药股份有限公司 | 用于治疗和/或预防脑梗塞的含有重组人胰激肽原酶的药物组合物 |
CN102361652A (zh) * | 2009-03-25 | 2012-02-22 | 琳得科株式会社 | 附着防止组合物、固体制剂及其制备方法 |
-
2013
- 2013-03-29 CN CN201310105812.8A patent/CN104069486B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100384991C (zh) * | 2004-08-20 | 2008-04-30 | 北京赛生药业有限公司 | 高纯度胰激肽原酶的制备方法及其药物制剂 |
WO2006088305A1 (en) * | 2005-02-15 | 2006-08-24 | Chong Kun Dang Pharmaceutical Corp. | Gastric-retentive controlled release mono-matrix tablet |
CN101134105B (zh) * | 2007-07-02 | 2011-04-20 | 广东天普生化医药股份有限公司 | 用于治疗和/或预防脑梗塞的含有重组人胰激肽原酶的药物组合物 |
CN102361652A (zh) * | 2009-03-25 | 2012-02-22 | 琳得科株式会社 | 附着防止组合物、固体制剂及其制备方法 |
Non-Patent Citations (1)
Title |
---|
《胰激肽原酶肠溶片效价测定的质量评价研究》;高恒莹,等;《临床药物治疗杂志》;20060331;第4卷(第3期);全文 * |
Also Published As
Publication number | Publication date |
---|---|
CN104069486A (zh) | 2014-10-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103118662B (zh) | 制备冻干速溶多相剂型的方法 | |
US11351184B2 (en) | Preparation of Pulsatilla saponin B4 for injection | |
CN102038648A (zh) | 治疗消化性溃疡的粉针剂及其制备方法 | |
CN105636590A (zh) | 眼病的治疗剂或预防剂 | |
CN103800367A (zh) | 治疗高血压的药物组合物及其制备方法 | |
CN102499923B (zh) | 一种药物组合物、其制备方法及用途 | |
CN107438613A (zh) | 用于预防或治疗感觉毛细胞死亡的化合物和方法 | |
WO2013189285A1 (zh) | 曲札茋苷在制备改善微循环障碍药物中的应用 | |
CN104069486B (zh) | 一种含有胰激肽原酶的药物组合物及其制剂 | |
US20100130604A1 (en) | Use of rosmarinic acid in manufacture of medicaments for treating or preventing hepatic and renal diseases | |
CN105395504B (zh) | 一种盐酸氟桂利嗪骨架缓释片及其制备方法 | |
CN106265581B (zh) | 一种氨甲环酸片及其制备方法 | |
KR20090095668A (ko) | 포르시토사이드 주사제와 그 제조 방법 | |
MXPA04010579A (es) | Una inyeccion hecha de lxeris sonchifolia hance para el tratamiento de las enfermedades cardio-cerebrales vasculares y enfermedades del fundus y metodo para producir la misma. | |
CN105125485A (zh) | 一种提高葛根素药物注射制剂稳定性注射药物的制备方法 | |
CN102228450A (zh) | 尼麦角林胶囊及其生产方法 | |
CN104800172B (zh) | 注射用卡络磺钠粉针剂和制法 | |
CN104706655A (zh) | 注射用环磷腺苷葡胺粉针剂药物组合物和制法 | |
CN105902564B (zh) | 一种治疗高血压的药物组合物及制备方法 | |
CN108785268A (zh) | 一种盐酸索他洛尔制剂及其制备方法 | |
CN105147709B (zh) | 一种替诺福韦二吡呋酯或其药用盐的用途 | |
CN104645322B (zh) | 一种复合磷酸酯酶肠溶片及其制备方法和应用 | |
CN114129528A (zh) | 一种具有临床优势的新型枸橼酸西地那非制剂及其制备工艺与应用 | |
CN104721153A (zh) | 注射用氨甲苯酸冷冻干燥粉针剂药物组合物 | |
CN101019837B (zh) | 银杏酮酯分散片及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee | ||
CP01 | Change in the name or title of a patent holder |
Address after: 130012, 672, pioneering street, hi tech Zone, Jilin, Changchun Patentee after: CHANGCHUN HAIYUE PHARMACEUTICAL Co.,Ltd. Address before: 130012, 672, pioneering street, hi tech Zone, Jilin, Changchun Patentee before: Changchun Haiyue Pharmaceutical Co.,Ltd. |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A pharmaceutical composition containing pancreatic kininogenase and its preparation Effective date of registration: 20231226 Granted publication date: 20160420 Pledgee: China Construction Bank Co.,Ltd. Changchun Science and Technology Sub branch Pledgor: CHANGCHUN HAIYUE PHARMACEUTICAL Co.,Ltd. Registration number: Y2023220000146 |